1
|
Castro-Escamilla O, Aguilar-Flores C, Mora-Velandia LM, Morán-Martínez K, Fernández-Madinaveitia DE, Lemini-López A, González-Palacios E, Maldonado-García C, Jurado-Santa Cruz F, Pérez-Montesinos G, Bonifaz LC. SEB Stimulation Induces Functional Pathogenic Features in Th17 Cells from Psoriasis Patients. J Invest Dermatol 2018; 138:2677-2681. [PMID: 29890166 DOI: 10.1016/j.jid.2018.05.024] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2017] [Revised: 05/25/2018] [Accepted: 05/29/2018] [Indexed: 11/26/2022]
Affiliation(s)
- Octavio Castro-Escamilla
- Unidad de Investigación Médica en Inmunoquímica, Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México City, México; Universidad Nacional Autónoma de México (UNAM), México City, México
| | - Cristina Aguilar-Flores
- Unidad de Investigación Médica en Inmunoquímica, Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México City, México; Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional (IPN), México City, México
| | - Luz María Mora-Velandia
- Unidad de Investigación Médica en Inmunoquímica, Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México City, México
| | - Karina Morán-Martínez
- Centro Dermatológico Dr. Ladislao de la Pascua, Secretaria de Salud de la Ciudad de México, México City, México
| | | | - Alicia Lemini-López
- Servicio de Dermatología, Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México City, México
| | - Elizabeth González-Palacios
- Centro Dermatológico Dr. Ladislao de la Pascua, Secretaria de Salud de la Ciudad de México, México City, México
| | - César Maldonado-García
- Centro Dermatológico Dr. Ladislao de la Pascua, Secretaria de Salud de la Ciudad de México, México City, México
| | - Fermín Jurado-Santa Cruz
- Centro Dermatológico Dr. Ladislao de la Pascua, Secretaria de Salud de la Ciudad de México, México City, México
| | - Gibrán Pérez-Montesinos
- Centro Dermatológico Dr. Ladislao de la Pascua, Secretaria de Salud de la Ciudad de México, México City, México
| | - Laura C Bonifaz
- Unidad de Investigación Médica en Inmunoquímica, Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México City, México.
| |
Collapse
|
2
|
Mora-Velandia LM, Castro-Escamilla O, Méndez AG, Aguilar-Flores C, Velázquez-Avila M, Tussié-Luna MI, Téllez-Sosa J, Maldonado-García C, Jurado-Santacruz F, Ferat-Osorio E, Martínez-Barnetche J, Pelayo R, Bonifaz LC. A Human Lin - CD123 + CD127 low Population Endowed with ILC Features and Migratory Capabilities Contributes to Immunopathological Hallmarks of Psoriasis. Front Immunol 2017; 8:176. [PMID: 28303135 PMCID: PMC5332395 DOI: 10.3389/fimmu.2017.00176] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2016] [Accepted: 02/07/2017] [Indexed: 02/06/2023] Open
Abstract
Innate lymphoid cells (ILC) are members of a heterogeneous family with a lymphoid origin that mimics the T helper (Th) cytokine profile. ILC are involved in early effector cytokine-mediated responses during infections in peripheral tissues. ILC also play an important role in chronic skin inflammatory diseases, including psoriasis. Although classical ILC express CD127, it has been recently reported that the presence of non-classical CD127- ILC populations and an early ILC precursor (EILP) CD127low. ILC development has predominately been investigated in mouse models. However, in humans, different transcription factors have been described for ILC identification. NFIL3 (nuclear factor, IL-3 regulated) is crucial for ILC development in response to IL-7. CD123 (IL-3Rα) is usually used to exclude basophils during ILC identification, however, it is unknown if in response to IL-3, NFIL3 could be relevant to induce ILC features in Lin- CD123+ populations in addition, is also unknown whether peripheral blood (PB) population with ILC features may have skin-homing potential to participate in skin inflammatory chronic diseases. Here, we report a Lin- CD123+ CD127low CD7+ CLA+ population that share some phenotypic properties with basophils, but expresses several transcription factors for ILC commitment such as inhibitor of DNA binding 2 (Id2), NFIL3, promyelocytic leukemia zinc finger (PLZF), thymocyte selection-associated high-mobility group box protein (TOX), and T cell factor-1 (TCF-1). In addition, this population expresses different ILC markers: CD132, CD90, CD161, α4 integrin, c-Kit, CRTH2, AhR, and IL-23R. IL-3 prevents apoptosis and increases their NFIL3, TOX, and PLZF expression. In PB, the CD123+ CD127low population is predominantly a conspicuous population that expresses T-bet and RORγt. The Lin- CD123+ CD127low population in PB has a limited Th type cytokine expression and highly expresses IL-8. The Lin- CD123+ CD127low population expresses skin-homing receptors (cutaneous lymphocyte antigen and CXCR4) and transmigrates through endothelial cells in response to SDF-1. An equivalent Lin- CD123low population was identified in control skin, which shows a broader phenotypic diversity and cytokine production, including IL-22 and IL-17. Remarkably, the CD123low population in the lesion and non-lesion skin of psoriasis patients expresses IL-17 and IL-22. Our findings suggest the identification of an alternative Lin- CD123+ CD127low population with ILC features endowed with migratory capabilities that might contribute to immunopathological hallmarks of psoriasis.
Collapse
Affiliation(s)
- Luz María Mora-Velandia
- Unidad de Investigación Médica en Inmunoquímica Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico; Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico
| | - Octavio Castro-Escamilla
- Unidad de Investigación Médica en Inmunoquímica Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico; Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico
| | - Andrés González Méndez
- Unidad de Investigación Médica en Inmunoquímica Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social , Mexico City , Mexico
| | - Cristina Aguilar-Flores
- Unidad de Investigación Médica en Inmunoquímica Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social , Mexico City , Mexico
| | - Martha Velázquez-Avila
- Unidad de Investigación en Enfermedades Oncológicas, Hospital de Oncología, Centro Médico Nacional 'Siglo XXI' , Mexico City , Mexico
| | - María Isabel Tussié-Luna
- División de Investigación, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico; Unidad de Investigación en Virología y Cáncer, Hospital Infantil de México "Federico Gómez", Mexico City, Mexico
| | - Juan Téllez-Sosa
- Centro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública , Cuernavaca, Morelos , Mexico
| | - César Maldonado-García
- Centro Dermatológico "Dr. Ladislao de la Pascua", Secretaria de Salud de la Ciudad de México , Mexico City , Mexico
| | - Fermín Jurado-Santacruz
- Centro Dermatológico "Dr. Ladislao de la Pascua", Secretaria de Salud de la Ciudad de México , Mexico City , Mexico
| | - Eduardo Ferat-Osorio
- Unidad de Investigación Médica en Inmunoquímica Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social , Mexico City , Mexico
| | - Jesus Martínez-Barnetche
- Centro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública , Cuernavaca, Morelos , Mexico
| | - Rosana Pelayo
- Unidad de Investigación en Enfermedades Oncológicas, Hospital de Oncología, Centro Médico Nacional 'Siglo XXI' , Mexico City , Mexico
| | - Laura C Bonifaz
- Unidad de Investigación Médica en Inmunoquímica Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social , Mexico City , Mexico
| |
Collapse
|